Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2065]

Incorporating liquid biopsies into clinical trials

Dr Daniel Hayes - University of Michigan Comprehensive Cancer Center, Ann Arbor...

Incorporating liquid biopsies into clinical trials ( Dr Daniel Hayes - University of Michigan Comprehensive Cancer Center, Ann Arbor, USA )

Big data, scientific wellness and transforming healthcare

Prof Leroy Hood - Systems Biology, Seattle, USA

Big data, scientific wellness and transforming healthcare ( Prof Leroy Hood - Systems Biology, Seattle, USA )

Bayesian adaptive trial designs for precision medicine

Dr Jack Lee - MD Anderson Cancer Center, Houston, USA

Bayesian adaptive trial designs for precision medicine ( Dr Jack Lee - MD Anderson Cancer Center, Houston, USA )

Genomic-driven clinical studies in breast cancer

Prof José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA

Genomic-driven clinical studies in breast cancer ( Prof José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA )

Patient-specific peptide vaccines

Prof Hans-Georg Rammensee - University of Tübingen, Tübingen, Germany

Patient-specific peptide vaccines ( Prof Hans-Georg Rammensee - University of Tübingen, Tübingen, Germany )

Proteogenomics in cancer research

Dr Henry Rodriguez - National Cancer Institute (NIH), Bethesda, USA

Proteogenomics in cancer research ( Dr Henry Rodriguez - National Cancer Institute (NIH), Bethesda, USA )

Delayed infection exposure as a trigger for childhood ALL

Prof Julia Hauer - Clinic for Pediatric Oncology, Düsseldorf, Germany

Delayed infection exposure as a trigger for childhood ALL ( Prof Julia Hauer - Clinic for Pediatric Oncology, Düsseldorf, Germany )

FDG-PET guidance allows substantial chemoreduction in Hodgkin lymphoma

Dr Peter Borchmann - Uniklinik Koeln, Cologne, Germany

FDG-PET guidance allows substantial chemoreduction in Hodgkin lymphoma ( Dr Peter Borchmann - Uniklinik Koeln, Cologne, Germany )

ZUMA 1: CD19 CAR T cells for refractory NHL

Dr Yi Lin, Mayo Clinic - Rochester, MN, USA

$ZUMA 1: CD19 CAR T cells for refractory NHL ( Dr Yi Lin, Mayo Clinic - Rochester, MN, USA )$

Risk and benefit of anti-coagulants for elderly patients with cancer-associated...

Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London...

Risk and benefit of anti-coagulants for elderly patients with cancer-associated venous thromboembolism ( Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London, Ontario, Canada )

Interim analysis of the JULIET study

Prof Gilles Salles - Université Claude Bernard, Lyon, France

Interim analysis of the JULIET study ( Prof Gilles Salles - Université Claude Bernard, Lyon, France )

400mg imatinib as good as 800mg for 10 year CML survival

Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany

400mg imatinib as good as 800mg for 10 year CML survival ( Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany )

More from ecancer